Clinical Trial Update: Long-term Efficacy and Safety of Subjects Approximately 3 Years After Priming With 2 Doses of GSK Bio's HRV Vaccine. [Phase 3]

View source ↗

Summary

A Phase 3 long-term follow-up study assessing efficacy and safety of GSK's HRV vaccine approximately 3 years after priming with 2 doses.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rotavirus Infection

Drugs mentioned

• HRV vaccine

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Rotavirus | Phase 3 | Status: COMPLETED | Results posted: 2017-02-23